[{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pharmaceuticals \/ Adhera Therapeutics"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pharmaceuticals \/ Adhera Therapeutics"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melior Pharmaceuticals \/ Melior Pharmaceuticals I","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pharmaceuticals \/ Melior Pharmaceuticals I"}]

Find Clinical Drug Pipeline Developments & Deals by Melior Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b ...

                          Brand Name : MLR-102

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 24, 2021

                          Lead Product(s) : Tolimidone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Recipient : Adhera Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Melior has uncovered a previously unreported therapeutic potential of MLR-1019 in PD. As such it represents a new class of PD therapeutic which may be the only drug candidate to address both movement and non-movement aspects of PD.

                          Brand Name : MLR-1019

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 29, 2021

                          Lead Product(s) : Armesocarb

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Adhera Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the intended acquisition, Adhera will continue clinical development of MLR-1019 (Armesocarb ). Melior Pharmaceuticals will receive Adhera stock plus royalties.

                          Brand Name : MLR-1019

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 07, 2021

                          Lead Product(s) : Armesocarb

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Adhera Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The planned Phase 2 study is intended to recruit 236 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone will be taken as an orally administered pill once a day.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 09, 2021

                          Lead Product(s) : Tolimidone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The Phase 2 clinical trial is intended to test tolimidone in subjects who were recently diagnosed with COVID19, but are not hospitalized. Tolimidone is expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complica...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 15, 2020

                          Lead Product(s) : Tolimidone

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Commonwealth of Pennsylvania’s COVID-19 Vaccines

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank